CDC will add acrylamide to the report
CDC is developing an assay for acrylamide or glycidamide adduct of the N-terminal b-chain of hemoglobin.
CDC is developing peptide-based standards and calibrators.
Assay reflects cumulative exposure over the last 3 months, precise and accurate, independent of fasting status and diurnal variation